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Background: Response to treatments is highly heterogeneous in cancer. Increased availability of biomarkers and targeted
treatments has led to the need for trial designs that efficiently test new treatments in biomarker-stratified patient subgroups.
Methods:We propose a novel Bayesian adaptive randomisation (BAR) design for use in multi-arm phase II trials where biomarkers
exist that are potentially predictive of a linked treatment’s effect. The design is motivated in part by two phase II trials that are
currently in development. The design starts by randomising patients to the control treatment or to experimental treatments that
the biomarker profile suggests should be active. At interim analyses, data from treated patients are used to update the allocation
probabilities. If the linked treatments are effective, the allocation remains high; if ineffective, the allocation changes over the
course of the trial to unlinked treatments that are more effective.
Results: Our proposed design has high power to detect treatment effects if the pairings of treatment with biomarker are correct, but
also performs well when alternative pairings are true. The design is consistently more powerful than parallel-groups stratified trials.
Conclusions: This BAR design is a powerful approach to use when there are pairings of biomarkers with treatments available for
testing simultaneously.
Response to treatment is highly heterogeneous in many diseases,
especially cancer. Some cancer treatments work extremely well in
subgroups of patients and provide less benefit, or even harm, in
other subgroups as exemplified by the interaction between KRAS
mutation status and cetuximab (Jimeno et al, 2009) or panitumu-
mab treatment in metastatic colorectal cancer (CRC; Peeters et al,
2013). The increasing availability of genetic and cancer genomic
information means that it is now feasible for clinical trials to be
based on genomic and proteomic information, that may stratify
cancers into discrete disease subgroups which are also predictive for
treatment response. To ensure high-quality information is available
to the clinician, robust evidence must be gathered on the effect of
treatment in these different subgroups. Development and validation
of biomarker–treatment pairings is therefore particularly important.
Heterogeneity of response makes the traditional drug develop-
ment and application process slow, costly and inefficient (Adams
and Brantner, 2006; Yap et al, 2010). Clinical trials that focus on all
patients often do not provide good evidence about differential
response in subgroups (Stewart and Kurzrock, 2009). Instead,
when treatments are expected to work only in subgroups, small
enriched phase III trials are more efficient. To ensure that
subgroups in phase III trials are suitably chosen, well-designed
phase II trials are important.
The BATTLE (Kim et al, 2011), I-SPY2 (Barker et al, 2009) and
FOCUS4 trials (Kaplan et al, 2013) are examples of trials using new
methodology to simultaneously evaluate several experimental
treatments and putative predictive biomarkers. The BATTLE and
I-SPY2 trials use Bayesian adaptive randomisation (BAR)
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methodology to assign more patients to treatments that have
performed well for similar patients that were previously recruited.
In the BATTLE trial, 255 heavily pretreated non-small cell lung
cancer (NSCLC) patients were randomised to one of four
molecular targeted therapies, according to a biomarker profile
determined from fresh tumour biopsies. Following an initial equal-
randomisation period, patients were adaptively randomised using
the emerging data. The same design, with different drug
combinations, is employed in the follow-on BATTLE-2 study
(Papadimitrakopoulou et al, 2013).
The I-SPY 2 trial is being conducted in the pre-operative
(neoadjuvant) breast cancer setting. Patients with potentially
curable early stage breast cancer have a baseline tumour biopsy
and biomarker panel assessment, then all receive standard pre-
operative treatment based on weekly paclitaxel. Similar to the
BATTLE studies, in the initial phase patients are randomised
equally between standard and experimental arms. After an interim
analysis of biomarker–treatment interactions, randomisation is
adapted so that patient allocation is increased to treatment arms
that show early signs of benefit.
The FOCUS4 trial in CRC uses group-sequential multi-arm
multi-stage methodology. After 16 weeks of chemotherapy, patients
are randomised to placebo or experimental treatments in parallel
biomarker-determined cohorts. Within each cohort, stopping rules
allow treatments to be dropped due to lack of benefit.
In this paper we describe and evaluate a novel design for use in
phase II cancer trials with several biomarker groups and novel
treatments. The design is proposed for use in two trials currently in
development; one for high-risk neo-adjuvant breast cancer and one
for platinum-resistant high-grade serous ovarian cancer (HGSOC).
In both cases, patients will be categorised into subgroups using
biomarkers. For each biomarker there is a linked treatment that,
prior to the trial starting, is thought likely to be effective on patients
who test positive for the biomarker. The design we describe
combines trial methodology from BATTLE, I-SPY 2 and FOCUS4
with novel ideas. We propose using BAR methodology so that
patient treatment allocation (by biomarker) can be moved away
from ineffective linked treatments in a cost- and time-efficient way.
Previously BAR has been shown to perform well in terms of power
in comparison with designs without interim analyses (Lee et al,
2010, 2012), and have similar operating characteristics to group-
sequential multi-arm multi-stage approach (Freidlin and Korn,
2013; Wason and Trippa, 2014). We elaborate further on the reasons
we chose to use a BAR design rather than a group-sequential design
in the discussion. Although designed with phase II oncology trials in
mind, the methodology will be suitable for use in other disease areas
where potential novel biomarkers and treatments pairings exist.
MOTIVATING EXAMPLE
As a motivating example for the methodology proposed in this
paper, we describe the SMARTer trials (Systematic bioMarker-
directed Adaptive Randomised Trials in breast and ovary cancer),
currently in development by our group. This is a proposal for two
independent multi-arm phase II trials to simultaneously test the
effectiveness of new therapies and also refine biomarkers that are
most likely to be the reliable predictors of treatment outcome. Each
trial will focus on three pairs of predictive biomarkers and linked
treatments, which will be compared with the control treatment of
chemotherapy alone.
Our approach represents a slight perspective shift compared
with studies such as BATTLE-2 and I-SPY 2. Both these studies
start with a collection of drugs that are deemed interesting for
further development in NSCLC and breast cancer, respectively, and
try to identify if one or more from a group of preselected
biomarkers can predict for clinical benefit. Conversely, we start
with a biomarker-driven subgroup that prior knowledge suggests
may represent a distinct disease subset. Examples include primary
platinum-resistant HGSOC with CCNE1 amplification or PTEN
loss (Etemadmoghadam et al, 2009; Cai et al, 2014). On the basis of
preclinical and early clinical data we then match this biomarker
with a treatment deemed likely to confer clinical benefit such as a
proteasome inhibitor in CCNE1-amplified HGSOC
(Etemadmoghadam et al, 2013). Targeting a subset of a particular
cancer type with an identifiable driver mutation has led to
remarkable successes in the past few years, exemplified by
vemurafenib treatment of BRAF-mutated melanoma (Chapman
et al, 2011) and crizotinib treatment of ALK-rearranged NSCLC
(Kwak et al, 2010). However, it is evident that many cancers
harbour multiple mutations, frequently targeting well annotated
pathways, such as the MAPK and PTEN/PI3K/mTOR pathways,
without a clear driver event. Efforts to target these pathways in
unselected patient populations have so far proven largely
unsuccessful. An advantage of our approach in this situation is
that, even if the original biomarker–drug pairing (e.g. PTEN loss
and a pan-PIK3CA inhibitor) does not show benefit, we still retain
considerable power to detect a drug effect in one of the other
biomarker-driven subsets (e.g., CCNE1 amplification) as detailed
in the following sections.
The objective is to use the accumulating clinical trial data
generated to identify suitable combinations of effective targeted
treatment and linked predictive biomarker to take forward for
testing in an enriched randomised phase III trial.
MATERIALS AND METHODS
Trial design. A maximum number of 350 patients are to be
recruited during each trial over 3 years. The trial has a total of four
interim analyses. The first is when 100 patients have been
recruited, and the other three are equally spaced throughout the
remainder of the trial, each taking place when the specified number
of patients have been recruited. A final analysis is conducted after
all patients have been assessed. Although the methodology can be
applied to trials with any number of experimental treatments, we
restrict attention only to three—labelled as T1, T2 and T3.
A control treatment is also included at all stages of the trial. Each
experimental treatment is linked with a biomarker—labelled as B1,
B2 and B3. The pairings represent the most plausible subgroups in
which the experimental treatments are likely to have a high
treatment effect. That is, for a particular biomarker there is a
paired treatment that is thought likely to be beneficial for patients
who are positive for that biomarker. Patients may be positive for
none, one, two or all three biomarkers.
At recruitment, a patient’s tumour is tested to determine which
biomarkers are positive. After testing, the patient is then
randomised to a treatment as described in the next section. In
the current design, the primary end points are binary: pathologic
complete response for the neoadjuvant breast cancer study and
6-month progression-free survival (PFS) rate for HGSOC. How-
ever, similar techniques could be applied for time-to-event
outcomes such as PFS or overall survival.
Initial stage. Patients who are recruited before the first interim
analysis are randomised equally between control and all experi-
mental treatments that are linked to their tumour biomarkers. As an
example, if a patient is positive for B1 and B3, they would be
allocated with equal probability to control, T1 and T3. Patients who
are negative for all biomarkers are still included in the trial, and are
randomised equally between all treatments and control.
Interim analyses and treatment allocation. The Supplementary
material provides a full technical description of the procedure used
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to allocate patients to treatments after the first interim analysis.
Here we provide a less technical overview of the approach.
The purpose of the interim analyses is to use the data gathered
during the trial to update the allocation probabilities. This is done
using a BAR procedure.
At each interim analysis, a Bayesian logistic regression model is
fitted that models the probability of treatment success as a function
of an intercept parameter, treatment effects, biomarker effects and
interactions between biomarker and treatment.
The Bayesian model requires prior distributions for all
parameters considered. For all parameters other than the
interactions, uninformative prior distributions are used (specifi-
cally, a uniform distribution between  10 and 10). For the
interaction parameters, we use informative priors for interactions
between linked treatment–biomarker pairs, and uninformative for
other interactions. The informative prior distribution used is a
normal distribution with mean and variance 1. The prior mean was
picked based on work in the Supplementary material.
The informative priors are used so that linked experimental
treatments will be favoured at the interim analyses unless there is
considerable evidence that an alternative treatment is superior.
From the Bayesian model, it is possible to find the posterior
probabilities that each experimental treatment is superior to
control for each biomarker profile. These probabilities are then
used to update the allocation probabilities to each arm using a
generalised version of the method used in Wason and Trippa
(2014), described fully in the Supplementary material. Briefly, the
allocation is set separately for every possible biomarker profile in
proportion to the posterior probabilities from the Bayesian model;
as the trial progresses, the increasing amount of evidence
accumulated results in a potentially quite different allocation
compared with the start. The allocation to the control treatment is
set so that, for each possible biomarker profile, the number of
patients allocated to the control is (on average) equal to the
number of patients on the best-performing experimental treat-
ment. This ensures that the power of the trial to detect significant
differences between effective experimental treatments and the
control treatment is maximised.
Given the posterior probability of each arm being better than
control, calculated at the most recent interim analysis, the
allocation only depends on the number of patients recruited to
each arm and in particular does not require knowledge of the
patient outcomes. Thus the allocation probability can be updated
after each patient is recruited with a similar amount of
administrative effort as a traditional randomised trial using
stratified randomisation. Note, however, that the posterior
probabilities are only updated at each interim analysis, as they
require full knowledge of patient outcomes.
Final analysis and hypothesis testing. The final analysis occurs
after all patients have been recruited and assessed. A similar model
to the one used at the interim analyses is used, except using a
classical logistic regression instead of a Bayesian version. Although
a Bayesian model could be used, we choose to use a non-Bayesian
final analysis so that the informative prior distributions are only
used to guide the adaptation at interim analyses, and the final
analysis is only based on data gathered during the trial.
There are a total of 12 hypotheses that may be tested. Three
correspond to the effect of an experimental treatment on patients
who are positive for its linked biomarker (i.e., B1–T1, B2–T2 and
B3–T3). A further six correspond to the effect of experimental
treatments on patients who are positive for non-linked biomarkers
(e.g., B1–T2, B1–T3 etc.). The remaining three hypotheses
correspond to the effect of each experimental treatment on
patients who are negative for every biomarker. These hypotheses
are specified in terms of the parameters in the logistic regression
(see Supplementary material).
Each hypothesis is rejected if the relevant Wald test statistic is
above 1.5 (equivalent to a one-sided P-value of o0.067). This is
chosen to control the linked-BAR design’s total probability of
making a type I error (known as the family-wise error rate (FWER))
at 0.4. As we are considering a phase II setting where significant
results will be tested in an appropriately powered phase III trial, we
do not aim to control the FWER at a stringent rate. In fact, stringent
control of FWER is not recommended in these cases (Wason et al,
2014). Previous work has shown that a high FWER can be optimal
when considering multi-arm phase II trials (Wason et al, 2013).
Any null hypotheses that are rejected will result in consideration
of a phase III trial in the relevant sub-population. For example, if
T1 is found to work well for B1-positive patients, then a phase III
trial of T1 vs control in B1-positive patients will be considered. If
multiple null hypotheses are rejected, then it may be that multiple
subgroups are considered in the same phase III trial. We note that
hypothesis testing results in this trial are non-binding and that
other factors will be considered before starting a phase III trial.
Delay. A factor that is present in most clinical trials is delay
between recruitment of patients and observation of their response to
treatment. In our case there is a 6-month delay. Delay causes loss of
efficiency in adaptive designs because at interim analyses there will
be patients who have been recruited but not yet assessed. Thus,
when the posterior probabilities are updated, patients who are not
yet assessed do not contribute information to this re-assessment.
The loss in efficiency depends on the recruitment rate of the trial, as
well as the delay. As an example, if a trial recruited all patients
within 6 months, then no adaptive procedure would be possible as
recruitment (and treatment assignment) would be finished by the
time the first patient provided information on the effectiveness of
treatments. We assume that accrual continues at a uniform rate
throughout the trial and is not paused at interim analyses.
An advantage of BAR is that it naturally deals with fixed delays
(Wason and Trippa, 2014). If a patient has been assessed, then they
are included in the re-assessment of allocation probabilities;
otherwise they are not.
Alternative designs. In order to benchmark the power and ethical
properties of the design proposed in this paper, we compare it with
three alternative designs. These are:
Parallel-group-stratified phase II trials. In this design, no interim
analyses are conducted. Patients are randomised to control or linked
treatments only throughout the trial. To keep the designs comparable,
we assume that patients who are negative for all biomarkers are
included and randomised equally between all the treatments.
Non-linked BAR design. This is similar to the linked-BAR design
proposed, with two important differences: (i) at the beginning,
patients are randomised equally between all available treatments;
(ii) the informative priors are not used at interim analyses (i.e., the
linked treatments are not prioritised). This design is chosen to be
similar to the design used for trials such as BATTLE (Kim et al,
2011). However, we do also use the improved procedure for setting
the allocation to control.
Equal-randomisation design. In this design, no interim analyses
are conducted. Patients are randomised equally between all
treatments throughout the trial, regardless of their biomarker profile.
RESULTS
Operating characteristics of design. In order to investigate the
operating characteristics of the linked-BAR design, we assess it and
the three comparison designs for eight different scenarios. In each
scenario, response is simulated using a logistic model, but with
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parameter values depending on the scenario. In all cases, the
biomarkers are assumed to have prevalence 0.3 and be indepen-
dently assigned to patients. In addition to the eight scenarios, we
considered different prevalence of the biomarkers and different
recruitment rates of the trial, as these factors will both affect the
power of the trial.
Table 1 summarises the various simulation scenarios we
consider. In the Supplementary material, these scenarios are
described in greater technical detail.
In each scenario, we simulated 2500 virtual trials for the two
BAR designs, and 10 000 for the two other designs (the difference
due to BAR simulations taking longer). Table 1 shows a summary
of the results of this simulation study. The ‘Recommend any’
column of scenario 1 shows the FWER of each design.
Interestingly, the FWER is highest using the stratified design, with
the linked-BAR having the lowest FWER. Subsequent power
comparisons between the designs should take this into account.
When there is a positive interaction between a linked pair of
treatment and biomarker (scenarios 2, 7), the parallel and linked-
BAR designs have the highest power. The non-linked BAR design
loses some power (5% in scenario 2 and 8% in scenario 7),
although still performs fairly well.
When there is an interaction between an unlinked pair (scenario 3),
the non-linked BAR approach performs best (74.0% power in
scenario 3), as first stage patients are randomised to all treatments.
The parallel trials procedure has poor power in that case (40.7%
power), with the linked-BAR procedure intermediate between the
two (67.6% power). These results indicate that the linked-BAR
procedure has the highest power to detect a linked interaction, but
still has fairly good power to detect non-linked interactions.
Although differences in power of between 5–10% may seem small,
they are equivalent to a reduction in sample size of between 15–25%.
Allocation. We examined how the probability of allocation
between arms evolves as a BAR trial progresses. We considered
two cases. In the first case we assumed that T1 provided a large
positive benefit in B1-positive patients and that T2 provided a large
negative effect in the same patients. In the second case, we reversed
these, as in scenario 8 of Table 1. For 2500 simulation replicates, we
kept track of the allocation probability of patients who were
positive for B1 as the trial progressed.
Figure 1 shows the average allocation of the linked-BAR
procedure (panel a) and the non-linked BAR procedure (panel b)
in case 1. The linked-BAR procedure begins by randomising B1-
positive patients equally between control and T1. This continues
until the first interim analysis after 100 patients are recruited. After
that the allocation to both falls slightly due to the BAR procedure
being used. However, the average allocation then increases towards
0.5 as time goes on. As the allocation to T1 increases, so does the
allocation to the control. The allocation to T2 and T3 decreases—
notice that allocation to T2 falls more quickly due to it being
inferior to control. A similar pattern is observed for the non-linked
BAR design, although the initial allocation is equal to all arms. In
addition, the allocation to T1 increases more slowly as informative
priors are not used. Note also that the average allocation to the
control group is higher than the average allocation to T1—this is
because the control allocation is set to match the experimental
treatment with the highest sample size, which by chance might not
be T1 for a particular trial.
Figure 2 shows the second case. In this case the linked-BAR
approach starts allocating half of B1-positive patients to T1, but
this drastically reduces after the first interim analysis and continues
to decline as more data is gathered. The average allocation to T2,
the superior treatment, increases as time goes on. The non-linked
BAR approach performs better in this case because the allocation
to T1 starts lower and drops more quickly due to a non-
informative prior distribution.
Varying the prevalence and recruitment rate. We next examined
the power of the four approaches to recommend T1 in B1-positive
patients under scenario 2 as the prevalence of B1 changes between 0.1
and 0.5 in increments of 0.025. The results of this are shown in
Figure 3. The power of all designs depends strongly on prevalence of
B1. The linked-BAR design has below 50% power when the
prevalence is 0.1, increasing to 90% power when the prevalence is 0.5.
Interestingly, the linked-BAR design generally has a slightly
higher power compared with the parallel trials design. This is
because of patients who are positive for multiple biomarkers; for
example a patient who is positive for B1 and B2 will always be
randomised equally between control, T1 and T2 in the parallel
trials design, but will be more likely to be put on the more effective
of T1 or T2 in the linked-BAR design.
We also investigated the sensitivity of the BAR methods to the
recruitment rate. For simulation scenario 2, the power of both the
non-linked BAR and linked-BAR designs remained at a similar
level, with evidence of a 2–3% reduction for the non-linked BAR
design as the recruitment rate increased from 7 patients per month
to 11 patients per month (data not shown).
Sensitivity analyses. In the Supplementary material, we provide
results showing how the power of the linked-BAR design depends
on the number of interim analyses and the prior mean used for the
interactions between linked pairs of biomarker and treatment. The
results show that five stages give sufficient power—increasing the
number of stages further does not increase the power further. A
prior mean of around 1 gives a good balance of power to detect
linked treatments and non-linked treatments.
DISCUSSION
In this paper we have proposed a new method for use in phase II
trials with several experimental treatments and biomarker
subgroups. The new method, the linked-BAR design, is proposed
for the situation where there are plausible pairings between the
experimental treatments and biomarkers. That is, an experimental
treatment is thought likely to have a positive treatment effect when
patients are positive for the linked biomarker. We allow for these
assumptions to be wrong by including interim analyses at which
allocation probabilities are updated according to the relative effects
of the treatments in different patient subgroups. We compared this
design with the strategy of only randomising patients to linked
treatments (i.e., not updating the allocation probabilities); an
alternative, non-linked, BAR design which starts off randomising
the patients to all available treatments and updates the allocation at
interim analyses in a similar manner to the linked-BAR method;
and a design that randomises patients equally throughout the trial
regardless of their biomarker profile. The linked-BAR design has
the highest power to detect a treatment effect for a linked
biomarker–treatment pair and close to the highest power to detect
a treatment effect between an unlinked pair. The design that
randomises all patients equally throughout the trial generally
performed poorly for testing hypotheses about the effect of
treatments in biomarker subgroups. This indicates that a
traditional trial design which ignores biomarker profiles of patients
will give poor evidence for deciding which treatments work well in
which biomarker groups.
The results show that there are situations where the non-linked
BAR design is preferable to the linked-BAR design. For example, if
there is no clear pairing between experimental treatments and
biomarkers. In the case where the pairings have a biological
rationale, or prior statistical evidence, then it is likely that the
linked-BAR method will be more powerful. In pure power terms,
the parallel trials design is only good when the prior linkages are
highly likely to be true—its power suffers otherwise.
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The choice of informative prior distribution in the linked-BAR
design is important. A higher prior mean (meaning patients are
more likely to be allocated to linked treatments), results in the
power to detect treatment effects between linked treatment–
biomarker pairs being higher than the parallel trials design.
However, its power to detect non-linked pairs suffers considerably.
Different clinical scenarios can be accommodated with BAR
methodology. First, if there is a hierarchy of biomarkers (e.g., a
patient who is positive for B1 and B2 may be thought more likely
to benefit from T1 than T2). Second, multiple treatments might be
linked to a certain biomarker (or vice versa). In both cases, suitably
changing the initial allocation and the prior distributions used for
the parameters can accommodate the requirements. Third, if
statistical interactions between biomarkers are plausible, then these
can be included in the final analysis.
We base the planned interim analyses on when the recruitment
milestones are met. It would be possible to instead plan analyses
for when a pre-specified number of patients have outcome data
available. This might well be preferable if the outcome had an
unpredictable delay (e.g., when time-to-event end points are used),
or when the recruitment rate could strongly vary during the trial.
Other biomarker-guided multi-arm trial designs have been
proposed, for example I-SPY 2 (Barker et al, 2009) and FOCUS 4
(Kaplan et al, 2013). It is hard to directly compare our design with
I-SPY 2 as there are few published details about the design available
currently. It appears from the protocol and clinical paper (Barker
Table 1. Description of simulation scenarios and simulation results for the eight scenarios
Design Recommend any
Recommend T1 in
negative patients
Recommend T1 in
B1-positive patients
Recommend T1 in
B2-positive patients
Recommend T2 in
B1-positive patients
Scenario 1: all experimental treatments have the same effect as control in every biomarker subgroup
NLB 0.418 0.056 0.051 0.056 0.050
LB 0.409 0.048 0.074 0.040 0.040
PT 0.498 0.069 0.069 0.071 0.065
ER 0.473 0.067 0.068 0.069 0.069
Scenario 2: as scenario 1, except T1 doubles the probability of response from 30% to 60% in patients who are positive for B1
NLB 0.856 0.051 0.767 0.058 0.057
LB 0.885 0.048 0.814 0.045 0.037
PT 0.903 0.070 0.817 0.057 0.068
ER 0.800 0.066 0.665 0.065 0.067
Scenario 3: as scenario 1, except T1 doubles the probability of response in patients who are positive for B2
NLB 0.829 0.056 0.059 0.740 0.058
LB 0.790 0.054 0.062 0.676 0.038
PT 0.672 0.066 0.070 0.407 0.073
ER 0.802 0.066 0.067 0.666 0.067
Scenario 4: T1 provides a moderate benefit in all biomarker groups
NLB 0.916 0.606 0.403 0.430 0.057
LB 0.912 0.600 0.503 0.356 0.032
PT 0.877 0.518 0.474 0.243 0.077
ER 0.869 0.526 0.367 0.362 0.070
Scenario 5: T1 provides a detrimental effect in patients positive for B1 with response rate falling from 0.3 to 0.11
NLB 0.428 0.061 0.000 0.059 0.066
LB 0.367 0.047 0.000 0.033 0.048
PT 0.475 0.066 0.000 0.056 0.068
ER 0.440 0.070 0.001 0.064 0.065
Scenario 6: as scenario 5, except T1 provides a detrimental effect in patients positive for B2 instead of B1
NLB 0.404 0.047 0.050 0.001 0.053
LB 0.406 0.051 0.073 0.000 0.044
PT 0.491 0.064 0.072 0.004 0.065
ER 0.450 0.070 0.070 0.001 0.069
Scenario 7: T1 provides large benefit in patients positive for B1 and a detrimental effect in patients positive for B2
NLB 0.817 0.049 0.725 0.000 0.056
LB 0.878 0.057 0.806 0.000 0.033
PT 0.889 0.068 0.805 0.002 0.069
ER 0.787 0.070 0.657 0.002 0.069
Scenario 8: T1 provides detrimental effect in patients positive for B1 and T2 provides a beneficial effect in those patients
NLB 0.848 0.056 0.002 0.046 0.774
LB 0.820 0.044 0.002 0.028 0.724
PT 0.662 0.071 0.001 0.063 0.412
ER 0.797 0.074 0.002 0.069 0.663
PT¼parallel trials design; NLB¼ non-linked BAR design; LB¼ linked-BAR design; ER¼ equal-randomisation design. Second to sixth columns give recommendation probabilities.
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et al, 2009) that the design is fairly similar to the non-linked BAR
design we consider in this paper, except that different ‘clinically
relevant’ combinations of biomarkers are considered. The methodol-
ogy we propose here (including the non-linked BAR design) has the
power advantage that the control allocation is carefully set to match
the experimental arm with highest sample size. On the other hand,
the I-SPY 2 design allows early termination if there is enough
evidence that an experimental treatment is superior and also uses
longitudinal MRI measurements to augment the allocation proce-
dure. Although we do not consider stopping rules here, they could
easily be incorporated within the design we propose in a similar
manner. In practice, if an allocation ratio for a treatment is below a
threshold value (e.g., 5%) it would likely be set to 0.
Although we do not consider FOCUS4 comparable to the
designs in this paper, due to it utilising a hierarchy of biomarkers,
the question remains of whether a group-sequential design which
specifies futility-stopping boundaries would be a superior choice to
our BAR design. Previous work (Freidlin and Korn, 2013; Wason
and Trippa, 2014) has shown that group-sequential and BAR
designs have similar statistical operating characteristics in the
context of a multi-arm trial without biomarker subgroups. The
0.6
0.4
0.2
0.0
0.6
0.4
0.2
0.0
0 100 200 300 0 100 200 300
Al
lo
ca
tio
n 
pr
ob
ab
ilit
y
Al
lo
ca
tio
n 
pr
ob
ab
ilit
y
Patient number Patient number
Treatment
Control
Experimental treatment 1
Experimental treatment 2
Experimental treatment 3
Treatment
Control
Experimental treatment 1
Experimental treatment 2
Experimental treatment 3
A B
Figure 1. Mean allocation probability for: (A) linked-BAR design and (B) non-linked BAR design as trial progresses for a B1-positive patient when
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Figure 2. Mean allocation probability for: (A) linked-BAR design and (B) non-linked BAR design as trial progresses for a B1-positive patient when
T2 provides benefit in B1-positive patients and T1 is detrimental in B1-positive patients. Lines represent the average over 2500 replicates.
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Figure 3. Power of the four designs to recommend T1 in B1-positive
patients as prevalence of B1 changes under scenario 2 in Table 1.
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main advantage of the BAR approach is that it is not obvious how a
group-sequential design would allow the linked treatments to be
prioritised early in the trial whilst still allowing non-linked
treatments to be allocated. A possibility would be to start by only
randomising between control and linked treatments and then
having a decision rule which would trigger randomising to non-
linked treatments, but it is not clear how one should do this.
We have considered a trial design that only assesses the
definitive end point. This is possible as the phase II end points we
use are observed relatively quickly after recruitment. If the end
points were longer-term then the methodology we propose in this
paper would require a suitable intermediate end point that was
known to be correlated with the final end point. Including
intermediate end points in a BAR design has been considered by
Berry et al (2010). We note also that the end point of progression
at 6 months could be analysed as PFS by suitably changing the
models used. We also could compare treatments for patients
positive for multiple biomarkers using the parameters of the
logistic regression.
Other relevant information, such as early progression from
patients who have not yet reached 6-month follow-up, or safety
and tolerability should also be considered at interim analyses. The
allocation from the BAR procedure should be treated as a
recommendation, and overridden as appropriate. For example, if
all experimental arms are clearly superior to the control, the trial
should likely be recommended for closing.
We have focused on the statistical properties of BAR designs in
this paper, but there are non-statistical issues to be considered also.
All types of adaptive designs will be accompanied by operational
challenges (Gallo, 2006), for example, managing the randomisation
and changing the allocation ratios after an interim analysis. It is
also problematic that the number of patients to be assigned to each
arm is not known in advance, as an adequate supply of drugs/
treatments is required. Although this is an issue for all adaptive
designs in biomarker-guided trials, BAR might experience greater
problems as there is greater scope for deviation from equal
randomisation. Another concern is potential investigator bias in
enrolling patients if a particular biomarker–treatment combination
is considered more attractive than others. This concern is
minimised by the fact that, in our design, all patients receive at
least standard-of-care chemotherapy and that the biomarker
information is unlikely to be available outside of the trial setting.
We conclude that the novel linked-BAR trial methodology
developed in this paper should provide a more cost-efficient trial
design for future cancer phase II trials. We believe that the linked-
BAR trial methodology will allow the most rapid and cost-efficient
way of both matching and testing novel predictive biomarkers and
new targeted treatments.
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